Placeholder Banner

BIO Comments to FDA on Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products, and Devices

July 26, 2023

BIO submitted general comments and specific recommendations to the FDA in response to the agency's request for information. (Docket FDA-2022-D-2870)

Download Full Comments Below
BIO Comment Letter - FDA-2022-D-2870 DCT
Discover More
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.